Centessa Pharmaceuticals (CNTA) Return on Sales (2022 - 2025)
Centessa Pharmaceuticals (CNTA) has disclosed Return on Sales for 4 consecutive years, with 16.18% as the latest value for Q3 2025.
- On a quarterly basis, Return on Sales fell 7893.0% to 16.18% in Q3 2025 year-over-year; TTM through Sep 2025 was 16.18%, a 7893.0% decrease, with the full-year FY2023 number at 22.05%, changed N/A from a year prior.
- Return on Sales was 16.18% for Q3 2025 at Centessa Pharmaceuticals, down from 15.36% in the prior quarter.
- In the past five years, Return on Sales ranged from a high of 62.75% in Q3 2024 to a low of 16.18% in Q3 2025.
- A 4-year average of 18.78% and a median of 18.96% in 2022 define the central range for Return on Sales.
- Peak YoY movement for Return on Sales: surged 4754bps in 2024, then plummeted -7893bps in 2025.
- Centessa Pharmaceuticals' Return on Sales stood at 19.61% in 2022, then fell by -27bps to 14.33% in 2023, then surged by 338bps to 62.75% in 2024, then tumbled by -126bps to 16.18% in 2025.
- Per Business Quant, the three most recent readings for CNTA's Return on Sales are 16.18% (Q3 2025), 15.36% (Q2 2025), and 1.74% (Q1 2025).